Effects of Dynamic Taping on Shoulder Isokinetics Strength and Muscle Fatigue.

June 25, 2026 updated by: Yin-Liang Lin, National Yang Ming Chiao Tung University

Effects of Dynamic Taping on Shoulder Strength, Fatigue, Corticomotor Control and Neuromuscular Control

Maintaining shoulder stability requires good neuromuscular control. Imbalances in shoulder internal and external rotator strength may increase the risk of shoulder injuries in overhead athletes, and the compromised fatigue resistance of the external rotators may worsen this imbalance during sports activities. Additionally, poor scapular neuromuscular control is associated with shoulder problems, such as shoulder impingement syndrome. Previous research has shown that individuals with shoulder impingement syndrome exhibit poor scapular motion control and altered corticomotor control. Poor scapular motion control, pain, functional impairment, and changes in corticomotor control interact to form a vicious cycle. Various treatments have been attempted to improve neuromuscular control, including taping. Most past studies have focused on the efficacy of rigid tape and kinesio tape, while dynamic tape has gained popularity in recent years. Due to its material properties, dynamic tape is theoretically able to absorb loads, provide force, and correct movements. However, there is currently a lack of evidence supporting the effectiveness of dynamic tape. No research has yet explored whether dynamic tape can provide force to increase muscle strength and reduce fatigue or whether its movement correction functions can improve neuromuscular control and corticomotor control. Therefore, this project plans to conduct an experiment to investigate the effects of dynamic tape on external rotator strength and fatigue in recreational overhead athletes, as well as its impact on neuromuscular control and corticomotor excitability in recreational overhead athletes with shoulder impingement syndrome. In the experiment, 37 healthy recreational overhead athletes will participate in three testing sessions spaced one week apart, receiving kinesio tape, dynamic tape, and sham tape. After taping, they will perform fatigue-inducing activities. Isokinetic strength of internal and external rotators will be measured before taping, after taping, and after fatigue-inducing activities to observe the effects of dynamic tape on muscle strength and fatigue compared to kinesio tape and sham tape.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
22

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

  • Name: Hsing-Shen Chen, MS
  • Phone Number: +886970789716

Study Locations

  • Taiwan
    • Taipei City
      • Taipei, Taipei City, Taiwan, 112
        • National Yang Ming Chiao Tung University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • practice overhead exercise more than six hours a week
  • aged 18 to 40 years old

Exclusion Criteria:

  • have a history of dislocation, fracture, or surgery of neck or upper extremity
  • a history of pain or injuries over the neck or upper extremities within the past 12 months
  • brain injury and neurological impairment
  • arm elevation angle is less than 150 degrees

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Sham Comparator: sham tape
Device: sham tape
sham
Active Comparator: kinesio tape
Device: kinesio tape
Kinesio taping will be applied to correct shoulder posture and facilitate shoulder external rotators
Experimental: dynamic tape
Device: dynamic tape
Dynamic tape will be applied to correct shoulder alignment and assist concentric contraction and eccentric control of external rotators

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Shoulder isokinetic muscle strength
Time Frame: Change from baseline shoulder isokinetic muscle strength after application of taping (about 4 minutes) and execution of a fatigue protocol (about 5 minutes)
Shoulder isokinetic internal and external muscle strength will be measured by dynamometer in 2 modes (concentric/concentric, concentric/eccentric) at 2 angular velocities (60°/s & 240°/s), 1 set of 5 repetitions for each angular velocities. Shoulder isokinetic muscle strength will be normalized by body weight (BW) and described with peak torque/BW (N·m·kg-1).
Change from baseline shoulder isokinetic muscle strength after application of taping (about 4 minutes) and execution of a fatigue protocol (about 5 minutes)

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Median frequency
Time Frame: Change from baseline shoulder isokinetic muscle strength after execution of a fatigue protocol (about 5 minutes)
The median frequency calculated from electromyographic data of shoulder internal and external rotators. The percentage change in median frequency will be calculated and will be described with percentage (%)
Change from baseline shoulder isokinetic muscle strength after execution of a fatigue protocol (about 5 minutes)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
National Yang Ming Chiao Tung University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 24, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 1, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 30, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 27, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 28, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 30, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
June 29, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 25, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • NYCU112007AF-1

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings